

November 25, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure of Related Party Transactions for the half year ended 30th September, 2022

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions for the half year / six months ended 30th September, 2022.

The same is also being made available on the website of the Company at www.glenmarkpharma.com

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

207	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Impex LLC	Fellow Subsidiary	Receivable				Not applicable		0.45	0.41									
208	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Generics SA	Fellow Subsidiary	Receivable				Not applicable		0.52	0.48									
209	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.	Fellow Subsidiary	Receivable				Not applicable		0.23	0.21									
210	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Arzneimittel GmbH	Fellow Subsidiary	Interest Expense				Not applicable	43.10											
211	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Arzneimittel GmbH	Fellow Subsidiary	Loan payable				Not applicable		3,658.65	3,483.67			Loan	euribor+2%	Not fixed	Unsecured	Business purpose		
212	Glenmark Holding S.A	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Loan taken				Not applicable	695.57					Loan	3.50%	Not fixed	Unsecured	Business purpose		
213	Glenmark Holding S.A	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Interest Payable on Loan taken				Not applicable	0.13											
214	Glenmark Holding S.A	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Loan payable				Not applicable		0.00	724.05			Loan	3.50%	Not fixed	Unsecured	Business purpose		
215	Glenmark Holding SA	Glenmark Specialty SA	Fellow Subsidiary	Payable				Not applicable		8.57	0.00									
216	Glenmark Holding SA	Glenmark Farmaceutica, Ltda	Fellow Subsidiary	Loan Receivable				Not applicable		3.89	4.20			Loan	5%	Not fixed	Unsecured	Business purpose		
217	Glenmark South Africa (Pty) Ltd.	Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Fellow Subsidiary	Loan given				Not applicable		490.46	427.14			Loan	0%	Not fixed	Unsecured	Business purpose		
218	Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Specialty SA	Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements)				Not applicable	98.80											
219	Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Specialty SA	Fellow Subsidiary	Payable				Not applicable		41.81	99.87									
220	Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Pharmaceuticals Kenya Ltd	Fellow Subsidiary	Sale of material & services				Not applicable	1.34											
221	Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Pharmaceuticals Kenya Ltd	Fellow Subsidiary	Receivable				Not applicable		2.51	1.33									
222	Glenmark Pharmaceuticals Egypt S.A.E.	Glenmark Pharmaceuticals Kenya Ltd	Fellow Subsidiary	Receivable				Not applicable		1.87	2.01									
223	Glenmark Pharmaceuticals Kenya Ltd	Glenmark Generics S. A.	Fellow Subsidiary	Payable				Not applicable	4.86											
224	Glenmark Pharmaceuticals Kenya Ltd	Glenmark Generics S. A.	Fellow Subsidiary	Receivable				Not applicable		4.72	0.00									
225	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Sale of material & services				Not applicable	500.00	181.48										
226	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Receivable				Not applicable		285.38	219.80									
227	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Expenses Reimbursed				Not applicable	0.24											
228	Glenmark Life Sciences Limited	Viso Farmaceutica S.L.U.	Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements)				Not applicable	35.00	4.77										
229	Glenmark Life Sciences Limited	Viso Farmaceutica S.L.U.	Fellow Subsidiary	Payable				Not applicable			3.59	8.11								
230	Glenmark Life Sciences Limited	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements)				Not applicable	50.00	26.21										
231	Glenmark Life Sciences Limited	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Payable				Not applicable			31.99	24.37								
232	Glenmark Life Sciences Limited	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Expenses Reimbursed				Not applicable	1.18											
233	Glenmark Life Sciences Limited	Glenmark Foundation	Enterprises over which significant influence exercised by key management personnel/directors	Expenditure incurred for CSR activities					70.00	10.00	0.00	0.00								
234	Glenmark Life Sciences Limited	Dr. Yasir Rawjee	MD & CEO	Remuneration				Not applicable	22.79											
235	Glenmark Life Sciences Limited	Mr. Tushar Mistry	Chief Financial Officer	Remuneration				Not applicable	5.02											
236	Glenmark Life Sciences Limited	Mr. Sumantra Mitra	Executive Director	Remuneration				Not applicable	8.74											
237	Glenmark Life Sciences Limited	Mr. Rudalf Corriea	Company Secretary & Compliance Officer	Remuneration				Not applicable	0.93											
238	Glenmark Life Sciences Limited	Mrs. Manju Agarwal	Independent Director	Sitting Fees				Not applicable	0.60											
239	Glenmark Life Sciences Limited	Mr. T L Easwar	Independent Director	Sitting Fees				Not applicable	0.50											
240	Glenmark Life Sciences Limited	Ms. Gita Nanyar	Independent Director	Sitting Fees				Not applicable	0.50											
241	Glenmark Life Sciences Limited	Mr. Sridhar Gorthi	Independent Director	Sitting Fees				Not applicable	0.80											
242	Glenmark Life Sciences Limited	Mr. Bhavesh Pujara	Chief Financial Officer	Remuneration				Not applicable	4.68											
243	Glenmark Pharmaceuticals Canada Inc.	Glenmark Pharmaceuticals Inc USA	Fellow Subsidiary	Expenses paid on behalf of others				Not applicable	2.18											
244	Glenmark Pharmaceuticals Canada Inc.	Glenmark Pharmaceuticals Inc USA	Fellow Subsidiary	Payable				Not applicable		1.86	3.95									
245	Glenmark Therapeutics Inc.	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	1.24											
246	Glenmark Therapeutics Inc.	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Payable				Not applicable		1.16	1.29									
247	Glenmark Pharmaceuticals Inc	Glenmark Generics SA	Fellow Subsidiary	Receivable				Not applicable		7.97	8.60									
248	Glenmark Pharmaceuticals Inc	Glenmark Specialty SA	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	1,868.49											
249	Glenmark Pharmaceuticals Inc	Glenmark Specialty SA	Fellow Subsidiary	Service Income Received				Not applicable	116.83											
250	Glenmark Pharmaceuticals Inc	Glenmark Specialty SA	Fellow Subsidiary	Payable				Not applicable		2,901.32	2,850.51									
251	Glenmark Pharmaceuticals Inc	Glenmark Farmaceutica Ltda	Fellow Subsidiary	Sale of Fixed Assets				Not applicable	18.11											
252	Glenmark Pharmaceuticals Inc	Glenmark Farmaceutica Ltda	Fellow Subsidiary	Receivable				Not applicable		14.42	34.42									
253	Glenmark Pharmaceuticals Inc	Glenmark Holding SA	Fellow Subsidiary	Loan taken				Not applicable	9,515.02					Loan	5%	3 Years	Unsecured	Business purpose		
254	Glenmark Pharmaceuticals Inc	Glenmark Holding SA	Fellow Subsidiary	Loan repaid				Not applicable	7751.70					Loan	5%	3 Years	Unsecured	Business purpose		
255	Glenmark Pharmaceuticals Inc	Glenmark Holding SA	Fellow Subsidiary	Interest Payable on Loan taken				Not applicable	155.07											
256	Glenmark Pharmaceuticals Inc	Glenmark Holding SA	Fellow Subsidiary	Loan payable				Not applicable		106.10	1,996.54			Loan	5%	3 Years	Unsecured	Business purpose		
257	Glenmark Pharmaceuticals Peru S.A	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	2.06											
258	Glenmark Pharmaceuticals Peru S.A	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Payable				Not applicable		0.11	3.60									
259	Glenmark Pharmaceuticals Peru S.A	Glenmark Specialty S.A.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	4.26											
260	Glenmark Pharmaceuticals Peru S.A	Glenmark Specialty S.A.	Fellow Subsidiary	Receivable				Not applicable		3.14	4.49									
261	Glenmark Pharmaceuticals Peru S.A	Glenmark Pharmaceuticals Colombia SAS	Fellow Subsidiary	Sale of Goods and Service				Not applicable	0.73											
262	Glenmark Pharmaceuticals Peru S.A	Glenmark Pharmaceuticals Colombia SAS	Fellow Subsidiary	Receivable				Not applicable		0.00	0.77									
263	Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Generics S.A.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	47.10											
264	Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Generics S.A.	Fellow Subsidiary	Receivable				Not applicable		3.31	6.30									
265	Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	1.81											
266	Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Receivable				Not applicable		7.86	6.11									
267	Glenmark Impex LLC	Glenmark Specialty SA	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)				Not applicable	24.79											
268	Glenmark Impex LLC	Glenmark Specialty SA	Fellow Subsidiary	Receivable				Not applicable		108.36	38.79									
269	Glenmark Specialty SA	Glenmark Pharmaceuticals Ecuador S.A.	Fellow Subsidiary	Sale of Goods and Service				Not applicable	6.14											
270	Glenmark Specialty SA	Glenmark Pharmaceuticals Ecuador S.A.	Fellow Subsidiary	Receivable				Not applicable		8.32	15.36									
271	Glenmark Specialty SA	Glenmark Holding SA	Fellow Subsidiary	Loan Payable				Not applicable		16,713.02	14,785.04			Loan	5%	Not fixed	Unsecured	Business purpose		
272	Glenmark Specialty SA	Glenmark Holding SA	Fellow Subsidiary	Interest Paid				Not applicable	381.96											
273	Glenmark Pharmaceuticals Europe Ltd.	Oliver Bourne	Director	Remuneration				Not applicable	14.40											
274	Glenmark Pharmaceuticals S.R.O.	Andrzej Gonddek	Director	Remuneration				Not applicable	18.34											
275	Glenmark Pharmaceuticals S.R.O.	Filip Ludvik	Director	Remuneration				Not applicable	5.17											
276	Glenmark Pharmaceuticals S.R.O.	Petr Podlipny	Director	Remuneration				Not applicable	6.26											
277	Glenmark Pharmaceuticals SK, S.R.O.	Andrzej Gonddek	Director	Remuneration				Not applicable	18.34											
278	Glenmark Pharmaceuticals SK, S.R.O.	Pavel Zachria	Director	Remuneration				Not applicable	11.09											
279	Glenmark Pharmaceuticals Inc. USA	Laura Lester	Director	Remuneration				Not applicable	26.03											
280	Glenmark Pharmaceuticals Inc. USA	Sanjeev Krishan	Director	Remuneration				Not applicable	65.08											
281	Glenmark Pharmaceuticals Inc.	Saira Ramasastry	Other related party	Consulting Fees				Not applicable	1.08											
282	Glenmark Pharmaceuticals Inc.	Rajeev Sharma	Director	Remuneration				Not applicable	18.29											
283	Glenmark Pharmaceuticals Inc.	Sanjeev Krishan	Director	Remuneration				Not applicable	65.08											
284	Glenmark Farmaceutica Ltda	Carlos Aguiar	Director	Remuneration				Not applicable	9.91											
285	Glenmark Farmaceutica Ltda	Neeraj Gupta	Director	Remuneration				Not applicable	8.11											
286	Glenmark Farmaceutica Ltda	Ana Sarmento	Director	Remuneration				Not applicable	4.41											
287	Glenmark Generics S.A	Victor Rodolfo Bertuccio	Director	Remuneration				Not applicable	7.03											
288	Glenmark Generics S.A	Gustavo Andrés Carrera	Director	Remuneration				Not applicable	5.90											
289	Glenmark Generics S.A	Carlos Eduardo Vieira de Aguiar	Director	Remuneration				Not applicable	9.91											
290	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.	Mariano Rozada	Director	Remuneration				Not applicable	17.03											
291	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.	Catalino Bocanegra	Director	Remuneration				Not applicable	5.14											
292	Under Glenmark Pharmaceuticals Europe Ltd.	Robson Tarciso de Faria	Director	Remuneration				Not applicable	10.52											
293	Glenmark Pharmaceuticals Peru SAC	Mauricio Guerra	Director	Remuneration				Not applicable	5.27											
294	Glenmark Pharmaceuticals Colombia SAS, Colombia	Mariano Hugo Rozada	Director	Remuneration				Not applicable	17.03											
295	Glenmark Pharmaceuticals Colombia SAS, Colombia	Mauricio Guerra Martinez	Director	Remuneration				Not applicable	5.27											
296	Glenmark Pharmaceuticals FZE	Dr Alok Chopra	Director	Remuneration				Not applicable	16.78											
297	Glenmark Pharmaceuticals FZE	Csaba Kantor	Director	Remuneration				Not applicable	51.23											
298	Glenmark Pharmaceuticals Kenya Ltd	Catherine Maina	Director	Remuneration				Not applicable	1.77											
299	Glenmark Pharmaceuticals Distribution s.r.o.	Marián Kolmikov	Director	Remuneration				Not applicable	11.38											
300	Glenmark Pharmaceuticals Nordic AB	Henric Juserius	Director	Remuneration				Not applicable	6.62											
301	Glenmark Pharmaceuticals Inc.	Bernard Munos	Director	Consulting Fees				Not applicable	1.57											
302	Glenmark Pharmaceuticals Inc.	Sona Saira Ramasastry	Other Related Party	Consulting Fees				Not applicable	2.15											
303	Glenmark Pharmaceuticals Europe Ltd.	Dipankar Bhattacharjee	Other Related Party	Consulting Fees				Not applicable	1.39											
304	Glenmark Holding S.A.	Hale & Tempest	Other Related Party																	

315	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Peru SAC.	Fellow Subsidiary	Investment			Not applicable	772.06	827.79										
-----	----------------------------------	------------------------------------	-------------------	------------	--	--	----------------	--------	--------	--	--	--	--	--	--	--	--	--	--

Notes:

- 1 All Related Party Transactions entered during the period were in ordinary course of the business and on arm's length basis.
- 2 Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.
- 3 Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.
- 4 Balances have been aggregated entity wise for all type of transactions and shown as net receivable/(payable)
- 5 As per the guidance note for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- 6 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors, as applicable, for financial year 2022-23.
- 7 All transactions in foreign currency, wherever applicable, have been converted and disclosed in INR.
- 8 Difference in opening and closing balances is on account of exchange rate fluctuation.
- 9 All figures in this disclosure are rounded off up to two decimals.